Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy.

Autor: Gheorghe, Liana¹, Preda, Carmen Monica¹ carmenmonica.preda@gmail.com, Trifan, Anca², Manuc, Mircea¹, Stanciu, Carol², Istratescu, Doina³, Popescu, Corneliu Petru⁴, Diculescu, Mircea-Mihai¹, Tieranu, Cristian George⁵, Manuc, Teodora¹, Stroie, Tudor¹, Iacob, Speranța¹, Iliescu, Laura⁶

Publikováno v: Journal of Gastrointestinal & Liver Diseases. Dec2022, Vol. 31 Issue 4, p437-443. 7p.

Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study

Autor: Jeong Heo, Yoon Jun Kim, Sung Wook Lee, Youn-Jae Lee, Ki Tae Yoon, Kwan Soo Byun, Yong Jin Jung, Won Young Tak, Sook-Hyang Jeong, Kyung Min Kwon, Vithika Suri, Peiwen Wu, Byoung Kuk Jang, Byung Seok Lee, Ju-Yeon Cho, Jeong Won Jang, Soo Hyun Yang, Seung Woon Paik, Hyung Joon Kim, Jung Hyun Kwon, Neung Hwa Park, Ju Hyun Kim, In Hee Kim, Sang Hoon Ahn, Young-Suk Lim

Publikováno v: The Korean Journal of Internal Medicine, Vol 38, Iss 4, Pp 504-513 (2023)

Background/Aims Despite the availability of direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection in Korea, need remains for pangenotypic regimens that can be used in the presence of hepatic impairment, comorbidities, or prior

Externí odkaz: https://doaj.org/article/95d31ece645e44a2ae4df56674553d45

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R).

Autor: Vermehren J; Gastro-Praxis Wiesbaden, Wiesbaden, Germany.; University Hospital Frankfurt, Frankfurt am Main, Germany., Serfert Y; Leberstiftungs-GmbH Deutschland, Hannover, Germany., Cornberg M; Hannover Medical School, Hannover, Germany., Stoehr A; ifi-Institute for Interdisciplinary Medicine, Hamburg, Germany., Klinker H; University Hospital Würzburg, Würzburg, Germany., Simon KG; MVZ Dres. Eisenbach, Simon, Schwarz GbR, Leverkusen, Germany., Teuber G; Hepatologische Schwerpunktpraxis, Frankfurt am Main, Germany., Deterding K; Hannover Medical School, Hannover, Germany.; Essen University Hospital, University of Duisburg-Essen, Essen, Germany., Schulze Zur Wiesch J; University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany., Jung MC; Leberzentrum München, München, Germany., Manns MP; Hannover Medical School, Hannover, Germany., Zeuzem S; University Hospital Frankfurt, Frankfurt am Main, Germany., Wedemeyer H; Leberstiftungs-GmbH Deutschland, Hannover, Germany.; Hannover Medical School, Hannover, Germany.; Essen University Hospital, University of Duisburg-Essen, Essen, Germany., Sarrazin C; University Hospital Frankfurt, Frankfurt am Main, Germany.; St. Josefs-Hospital Wiesbaden, Wiesbaden, Germany.

Publikováno v: Zeitschrift fur Gastroenterologie [Z Gastroenterol] 2020 Sep; Vol. 58 (9), pp. 841-846. Date of Electronic Publication: 2020 Sep 18.

Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection

Autor: Hyun Phil Shin

Publikováno v: The Korean Journal of Internal Medicine, Vol 38, Iss 4, Pp 454-455 (2023)

Externí odkaz: https://doaj.org/article/57b8b8deaccb4399ad4731616906b68c